Ovid Therapeutics (US:OVID) ZACKSยท2025-03-11 14:10Group 1 - Ovid Therapeutics reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.16, and an improvement from a loss of $0.22 per share a year ago, resulting in an earnings surprise of 18.75% [1] - The company posted revenues of $0.08 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 45.71%, compared to year-ago revenues of $0.14 million [2] - Ovid Therapeutics shares have declined approximately 47.6% since the beginning of the year, contrasting with the S&P 500's decline of 4.5% [3] Group 2 - The earnings outlook for Ovid Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.15 on revenues of $0.15 million, and -$0.64 on revenues of $0.55 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Ovid Therapeutics belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]